Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protalix Biotherapeutics Inc PLX

Healthcare Biotechnology
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the... see more

Recent & Breaking News (NYSEAM:PLX)

Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil

GlobeNewswire December 27, 2016

Protalix BioTherapeutics Announces Last Patient Enrolled in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis

GlobeNewswire December 22, 2016

Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil

GlobeNewswire December 14, 2016

Protalix BioTherapeutics Announces Investor Call

GlobeNewswire December 1, 2016

Protalix BioTherapeutics Announces Private Note Exchanges and Private Placement of Secured Convertible Notes due 2021

GlobeNewswire December 1, 2016

Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

GlobeNewswire November 30, 2016

Protalix BioTherapeutics Provides Update and Reports 2016 Third Quarter Results

GlobeNewswire November 9, 2016

Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease

GlobeNewswire August 10, 2016

Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results

GlobeNewswire August 8, 2016

Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis

GlobeNewswire July 7, 2016

Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings

GlobeNewswire June 6, 2016

Protalix BioTherapeutics to Present at the Jefferies 2016 Global Healthcare Conference

GlobeNewswire June 2, 2016

Protalix BioTherapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2016

Protalix BioTherapeutics Reports Fiscal Year 2015 Financial Results and Provides Corporate Update

GlobeNewswire March 8, 2016

Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium(TM) 2016

GlobeNewswire March 3, 2016

Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposium(TM) 2016

GlobeNewswire February 22, 2016

Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting With FDA

GlobeNewswire November 16, 2015

Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results

GlobeNewswire November 9, 2015

Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease

GlobeNewswire October 19, 2015

Protalix BioTherapeutics Sells Its Share in Collaboration Agreement for ELELYSO and a 6% Equity Stake in Protalix to Pfizer for a Total of $46 Million

GlobeNewswire October 13, 2015